AU Patent

AU2015341490C1 — Buprenorphine dosing regimens

Assigned to Indivior UK Ltd · Expires 2021-03-11 · 5y expired

What this patent protects

The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.

USPTO Abstract

The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.

Drugs covered by this patent

Patent Metadata

Patent number
AU2015341490C1
Jurisdiction
AU
Classification
—
Expires
2021-03-11
Drug substance claim
No
Drug product claim
No
Assignee
Indivior UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.